All Blogs

Aug 01, 2024

FDA Approved Stryker’s Spine Guidance 5 Software Featuring Copilot On July 30, 2024, Stryker, a global leader in medical technologies, announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration. This first-to-market t...

Jul 31, 2024

As cancer continues to be a leading cause of mortality worldwide, there is a growing urgency to develop innovative oncolytic virus therapies that can effectively target and eradicate cancer cells. With its unique ability to selectively infect and replicate within tumor cells, oncolytic virus therapy has emerged as ...

Jul 30, 2024

The FDA Advisory Committee Considers the AEGEAN Phase III Trial Data in their Review of IMFINZI for Treating Resectable NSCLC The FDA's Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s IMFINZI (durvalumab) achieved the primary endpoint of event-free survival (EFS) in resectable non-small...

Jul 29, 2024

With an estimated 1 million patients affected in the US, thyroid eye disease is a burden for some disorders which become sight-threatening in upto 5% of the cases. Until today, only one thyroid eye disease treatment drug for adults has been approved by the FDA.  Developed by Horizon Therapeutics (now acquir...

Jul 26, 2024

Gene therapy is becoming a promising solution for retinal degenerative diseases, as the retina offers an excellent setting for studying and treating eye conditions. Importantly, it was the first tissue to receive approved gene therapy for genetic disorders in the United States. To date, only one retinitis pigmentos...

Jul 25, 2024

STRATA Skin Sciences Announced That the Ministry of Health, Labor and Welfare Approved the XTRAC Momentum™ 1.0 Device in Japan, Specifically Designed to Treat Inflammatory Skin Conditions On July 22, 2024, STRATA Skin Sciences, Inc., a medical technology company specializing in developing, commercializing, and m...

Mar 12, 2025

Obesity is the second leading cause of preventable death, associated with a range of inflammatory conditions that contribute to cardiovascular disease, diabetes, respiratory problems, mental health issues, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This represents a significant public heal...

Jul 23, 2024

CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...

Jul 22, 2024

Conventional  IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....

Jul 19, 2024

After a few days of investor anxiety, Arcutis Biotherapeutics announced that the FDA has approved ZORYVE for a new indication: atopic dermatitis. The FDA was scheduled to announce its decision on ZORYVE (roflumilast) for this new use on the 7th of this month, but the date passed without news. In an uncommon move to...